Mandate

Vinge advises ABG, SEB and Swedbank in connection with a directed share issue in Hemfosa

June 20, 2018

Vinge advises ABG Sundal Collier, Skandinaviska Enskilda Banken and Swedbank who are acting as Joint Lead Managers and Bookrunners in connection with Hemfosa Fastigheter’s directed share issue, on the basis of an authorisation from the annual general meeting, of 10 million common shares, raising proceeds of SEK 1,085 million.

Hemfosa Fastigheter is a Swedish property company focused on community service properties in the Nordic region, with its largest tenants being the Swedish state and municipalities. Hemfosa’s common share has been listed since March 2014 and its preference share since December 2014, both on Nasdaq Stockholm.
 
Vinge’s team consists of Erik Sjöman, Dain Hård Nevonen and Sofie Bjärtun.
 

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026